Olr728 inhibitors are a specialized class of compounds that specifically target and modulate the activity of the Olr728 receptor, a member of the olfactory receptor family. Olfactory receptors, which are typically associated with the detection of odor molecules, are G protein-coupled receptors (GPCRs) that play significant roles in various physiological processes. The inhibition of Olr728 involves the interaction of these inhibitors with the receptor's active site, resulting in the alteration of its normal signaling pathways. These inhibitors often exhibit a high degree of specificity and affinity for Olr728, ensuring that their modulatory effects are precisely targeted, thereby minimizing off-target interactions. The molecular design of Olr728 inhibitors involves a thorough understanding of the receptor's structure, including its binding pockets and key amino acid residues that interact with the inhibitory compounds.
The development of Olr728 inhibitors encompasses various synthetic and analytical techniques to ensure the efficacy and specificity of these compounds. Chemical synthesis of these inhibitors often involves complex multi-step reactions to introduce functional groups that enhance binding affinity and selectivity towards the Olr728 receptor. Analytical techniques, such as X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, are employed to elucidate the structural interactions between the inhibitors and the Olr728 receptor. Additionally, computational modeling and molecular docking studies are utilized to predict the binding modes and optimize the chemical structures of these inhibitors. The precise control over the chemical properties of Olr728 inhibitors, such as solubility, stability, and bioavailability, is crucial for their effective application in research settings. As a result, Olr728 inhibitors represent a significant advancement in the field of receptor-targeted modulation, providing valuable insights into the functional dynamics of olfactory receptors beyond their traditional roles in olfaction.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Afatinib-d4 | 850140-72-6 (unlabeled) | sc-481821 | 10 mg | $4665.00 | ||
EGFR inhibitor, potentially disrupting proteins in EGFR signaling pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
HER2 and EGFR inhibitor, potentially affecting proteins in associated signaling pathways. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1/2 inhibitor, potentially impacting proteins in JAK-STAT signaling pathways. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
EGFR tyrosine kinase inhibitor, potentially affecting proteins in the EGFR signaling pathway. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
BCR-ABL and Src family kinase inhibitor, potentially disrupting proteins in leukemia signaling pathways. | ||||||
Zanubrutinib | 1691249-45-2 | sc-507434 | 5 mg | $360.00 | ||
Bruton's tyrosine kinase inhibitor, potentially affecting proteins in B-cell receptor signaling pathways. | ||||||
Encorafenib | 1269440-17-6 | sc-507422 | 1 mg | $115.00 | ||
BRAF inhibitor, potentially disrupting proteins in the MAPK/ERK pathway. | ||||||
CAL-101 | 870281-82-6 | sc-364453 | 10 mg | $193.00 | 4 | |
PI3Kδ inhibitor, potentially impacting proteins involved in B-cell signaling pathways. | ||||||
Baricitinib | 1187594-09-7 | sc-364730 sc-364730A | 5 mg 25 mg | $200.00 $664.00 | ||
JAK1/2 inhibitor, potentially affecting proteins in JAK-STAT signaling pathways. | ||||||